Skip to content
IFPMA Twitter
IFPMA LinkedIn
IFPMA Youtube
IFPMA Slideshare
IFPMA Flickr
IFPMA RSS
Search for:
Primary Menu
Who We Are
IFPMA in Brief
Our Governance and Leadership
Our Membership
Full Members
Associations
Companies
Affiliate Members
Our Experts
Join Us
Topics
News Center
News Releases
Blog
Global Health Matters
Science Matters
DG’s Column
Statements
Resources
Publications
News Releases
Statements
Position Papers
Publications
External Studies
Infographics
Event Highlights
Multimedia
Interviews
Videos
Slides
IFPMA Interactive Platforms
IFPMA COVID-19 Hub
Global Health Progress
50 Years of Global Health Progress
Events
Upcoming IFPMA Events
Geneva Pharma Forums
Assemblies
Other IFPMA Events
IFPMA in External Events
IFPMA Press Briefings
Past IFPMA Events
Geneva Pharma Forums
Assemblies
Other IFPMA Events
IFPMA in External Events
IFPMA Press Briefings
Partners
BCR
Inventing Medicines and Vaccines
Strengthening Regulatory Systems
Ethics and Business Integrity
Boosting Innovation and Access
Tackling Global health challenges
Climate change
Economic footprint
IP
Sustainable innovation
Value of innovation
spotlight
Value of innovation
African Medicines Agency
Biosimilars
Biotherapeutic medicines
Falsified medicines
Import testing
Pharmacovigilance
Quality, safety, and efficacy
Regulatory conferences
Regulatory system strengthening / Harmonization
Supply chain
The Africa Regulatory Network (ARN)
The ARN: Le réseau africain de réglementation pharmaceutique
spotlight
Pharmacovigilance
IFPMA Code of Practice (2019)
Our Ethos in Action
Our Ethos
Code eLearning Tool
IFPMA Notes for Guidance
IFPMA Complaint Operating Procedure
How to File a Code Complaint
Complaint Submission Form
Cases
Business Ethics for APEC SMEs Initiative
Consensus Framework for Ethical Collaboration
spotlight
IFPMA Code of Practice (2019)
Access to medicines
Global Policy Principles on Digital Health
Health technology assessment
IP
Technology Transfer
Trade
spotlight
Access to medicines
Ageing
Antimicrobial resistance
Cancer
Child and maternal health
COVID-19
Diabetes
Ebola
Falsified medicines
HIV/AIDS
Influenza
Malaria
Mental and neurological disorders
Neglected tropical diseases
Non-communicable diseases
Pandemic Preparedness
Public health implications of the implementation of the Nagoya Protocol
Rare diseases
Supply chain
Sustainable development goals
Tuberculosis
Universal Health Coverage
Vaccination confidence
Vaccines innovation
Vaccines protect communities
Vaccines sustainability
Value of immunization
Viral hepatitis
spotlight
Universal Health Coverage
Home
>
Tag: COVID-19
Tag: COVID-19
IFPMA COVID-19 Innovation Timeline
Pharma analysis of lessons learned from COVID-19 pandemic informs and offers shared solutions to consolidate innovation successes and improve equitable access for future pandemic response
COVID-19 vaccines and treatments output continues apace; as health systems and last mile hurdles remain collective stumbling blocks
Joint Guidance on Virtual and Hybrid International Medical Congresses
Global biopharmaceutical industry early response to Omicron
As COVID-19 vaccine output estimated to reach over 12 billion by year end and 24 billion by mid-2022, innovative vaccine manufacturers renew commitment to support G20 efforts to address remaining barriers to equitable access
Momentum of COVID-19 vaccine manufacturing scale up sufficient for step change in distribution
IFPMA Statement at the 11th APEC High-level Meeting on Health and the Economy - Session title: Incorporating Health Equity into Trade and Supply Chains for Vaccines and Medical Products
IFPMA Statement at the 71st session of the WHO Regional Committee for Africa: Special Event on the COVID-19 Response in the WHO AFRO Region
IFPMA Statement at WTO-WHO High Level Dialogue “Expanding COVID-19 Vaccine Manufacture to Promote Equitable Access” – Session title: Looking ahead
COVAX launches Marketplace to match buyers and sellers of critical manufacturing suppliers and speed up global access to COVID-19 vaccines through COVAX
ACT-Accelerator 1-Year Anniversary: the biopharmaceutical industry is committed to continue to play a critical role across ACT-A and accelerate equitable and fair access to COVID-19 tools
BIO-DCVMN-IFPMA COVID-19 Press Briefing - 23 April 2021 (Video)
COVID-19 vaccine industry cautions immediate action needed to remove manufacturing supply barriers to meet production targets and keep on course to equitable and fair access to COVID-19 vaccines
IFPMA statement at WTO event “COVID-19 and Vaccine Equity: What can the WTO Contribute”
Pharma delivers COVID-19 solutions, but calls for the dilution of intellectual property rights are counterproductive
Innovative and generic & biosimilar pharmaceutical industries unite on commitment to equitable access to COVID-19 medicines and vaccines, while flagging where further help is needed from others
IFPMA/IGBA “Considerations on equitable access to COVID-19 medicines and vaccines”
IFPMA statement on “Intellectual Property and COVID-19”
IFPMA Statement for the Special session of the Executive Board on implementation of Resolution WHA73.1
5 lessons as COVID-19 unfolds for future pandemics – Insights from the biopharmaceutical industry
WHO PAHO 72nd Regional Committee: COVID-19 Pandemic in the Region of the Americas
Innovative health industries united in welcoming UNGA Resolution on “Comprehensive and Coordinated Response to the COVID-19 Pandemic”
Innovative vaccine and medicine industry applaud country commitments to COVAX Facility
IFPMA Statement on the G-FINDER Report “Landscape of Emerging Infectious Disease R&D: Preventing the Next Pandemic”
Thomas Cueni at the New World Model Virtual Event 2020 organized by WFZO
IFPMA Statement to G20 Health and Finance Ministers
Safety of vaccinated individuals is the top priority in development of COVID-19 vaccines
WHO EURO 70th Regional Committe: The response to the COVID-19 pandemic and lessons learned
Global Biopharma CEO/Top Executives COVID-19 Media Briefing – COVID-19 therapeutics-3 September 2020 (Video)
1
2
Next »
Other Tags
Access
Access to antiretrovirals
Access to Medicines
Access to vaccines
Africa
AMR
AMR Industry Alliance
Anti-Counterfeit
Antibiotics
antimicrobial resistance
antivirals
Biosimilars
Biotherapeutic Medicines
Biotherapeutics
Cancer
Clinical Trials
Code of Practice
collaboration
Counterfeit Medicines
Counterfeits
COVID-19
COVID-19 vaccines
Dementia
Developing World
Diabetes
Economic footprint
Epidemics
Ethics
Event Highlights
Fake Medicines
Fakes
Falsified Medicines
Fight the Fakes
Flu
Global Health
global health security
harmonization
Health
Health Partnerships
HIV/AIDS
IFPMA
IFPMA Assembly
IFPMA Statement
Immunization
Incremental Innovation
Influenza
Infographic
Infographics
Innovation
Innovation ecosystem
Intellectual Property
IP
Malaria
MDGs
Medicines
Mental and Neurological Disorders
NCDs
Neglected Tropical Diseases
News Releases
Non-Communicable Diseases
Novel Coronavirus (COVID-19)
NTDs
pandemic
Pandemic Influenza
Pandemic preparedness
pandemics
partnership
Partnerships
Pharma
Pharmacovigilance
Position Paper
Prevention
Publications
Public Health
Quality
R&D
Regulatory
regulatory systems
Related Links
Research
Safety
SDGs
Seasonal Influenza
Statements
Supply chain
Sustainable Development Goals
Sustainable Innovation
trade
Treatments
Tuberculosis
UHC
Universal Health Coverage
Vaccine
Vaccines
Value of Innovation
Videos
WHA
WHO
WIPO
Women’s Cancers